SO YOU DRIVE to the local park for your morning walk, drive and take a Metro to your office, where you grab the lift to the third floor, and then you repeat the commute in the evening. If you have to queue up for an autorickshaw, you crib about last-mile connectivity to your doorstep, instead of walking that mile.
That’s rising urbanisation and sedentary lifestyles for you. The bane of modern India. But they are a boon for pharmaceutical companies such as Eli Lilly & Co, whose 146-year history has been powered by a list of firsts: the first treatment for pernicious anaemia, the first mass-produced antibiotic, the mass-produced Salk polio vaccine, human insulin, and pills for clinical depression and schizophrenia, among others.
Lilly is now betting that its drugs for obesity and diabetes will power its revenues into a higher trajectory. Especially as obesity and diabetes are like the proverbial chicken and egg situation: which came first? Lilly’s portfolio also has your heart covered (obesity and diabetes can get your heart).
RESPONDING TO THE DUAL CRISIS
US-based Lilly is no stranger to India. In 1993, it set up a unit to bring its treatments for diabetes, a range of cancers, osteoporosis, rheumatoid arthritis, men’s health, and growth hormone deficiency.
Now, it aims to bring to India its hugely successful drug Mounjaro that is used to treat Type 2 diabetes and as an anti-obesity drug for adults. In the US, Lilly has launched two different brands: Zepbound for obesity; and Mounjaro for Type 2 diabetes. In both, the active ingredient is tirzepatide. Mounjaro’s revenue exceeded $5 billion in 2023, its first full year on the market.
According to the FDA, approximately 70% of American adults are obese or overweight, and many of those overweight have a weight-related condition.
Denne historien er fra March 31, 2024-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra March 31, 2024-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Pension Scheme - Safety Net
The move to introduce the UPS has evoked mixed reactions. Analysts believe its funding will have limited impact on the fiscal math
The Reit Choice?
Real Estate Investment Trusts (Reits) Are Gaining Traction As Interest Rates Stabilise. But Returns Could Be Affected By Adverse Economic Conditions And Market Volatility
CORPORATE - Calling to Account
The sudden exit of Byju's auditor BDO marks the latest in a long series of setbacks for the edtech firm
EMPLOYMENT: Skills Push
The skill development ministry plans to partner with the UGC to improve the employability of undergraduates
Building on a Vision
L&T'S CHAIRMAN EMERITUS A. M. NAIK HAS BUILT A MAMMOTH ENTERPRISE THAT IS BUILDING A NEW INDIA, FROM ITS METRO RAIL SYSTEMS TO THE RAM TEMPLE
"KYS more important than KYC"
Vijay Kedia is a renowned equity investor; the value of his listed portfolio stands at around ₹1,750 crore
ROXX STAR
THE THAR ROXX COMBINES LUXURY WITH PERFORMANCE TO MAKE A STRONG STATEMENT IN THE MID-SIZE SUV SEGMENT
HIT THE GROUND RUNNING
Smartwatches have become indispensable tools for runners, offering real-time insights into pace, distance, heart rate, and more. Here are a few you can consider
TURNING THE TABLES
INDIA'S FURNITURE MARKET IS POISED FOR A GLOBAL TAKE-OFF. ALREADY, A HOST OF GLOBAL BRANDS HAVE MADE THE COUNTRY THEIR HOME, BUT INDIAN COMPANIES ARE NOT TOO FAR BEHIND
THE EVOLUTION OF ATHERA
IDENTIFYING OPPORTUNITIES IN ADVANCE HAS STOOD THIS BENGALURU-BASED VC FUND IN GOOD STEAD. NOW, WITH A HEIGHTENED FOCUS ON TECHNOLOGY, IT WANTS TO SUSTAIN THE SUCCESS
